Reply to "Response to "CD20 Positive Cells Are Undetectable in the Majority of Multiple Myeloma Cell Lines and Are Not Associated With a Cancer Stem Cell Phenotype". Haematologica 2012;97(7):1110-1114

Haematologica - Italy
doi 10.3324/haematol.2012.077727
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Ferrata Storti Foundation (Haematologica)

Related search

High Levels of Circulating CD34+ Cells at Autologous Stem Cell Collection Are Associated With Favourable Prognosis in Multiple Myeloma

British Journal of Cancer
Cancer ResearchOncology
2011English

Response to Dexamethasone Is Glucose-Sensitive in Multiple Myeloma Cell Lines

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2011English

Rituximab in CD20 Positive Multiple Myeloma

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2007English

CD133+ Glioblastoma Stem-Like Cells Are Radiosensitive With a Defective DNA Damage Response Compared With Established Cell Lines

Clinical Cancer Research
Cancer ResearchOncology
2009English

Four Proteins Governing Overangiogenic Endothelial Cell Phenotype in Patients With Multiple Myeloma Are Plausible Therapeutic Targets

Oncogene
Cancer ResearchGeneticsMolecular Biology
2011English

Bruceantin Inhibits Multiple Myeloma Cancer Stem Cell Proliferation

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2016English

Impact of Tandem Autologous Stem Cell Transplantation and Response to Transplant in the Outcome of Multiple Myeloma

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2012English

Β-Arrestins Regulate Stem Cell-Like Phenotype and Response to Chemotherapy in Bladder Cancer.

Molecular Cancer Therapeutics
Cancer ResearchOncology
2019English

WARNING: G‐401 and SK‐NEP‐1 Cell Lines Are Not Wilms Tumor Cell Lines

Pediatric Blood and Cancer
OncologyChild HealthHematologyPerinatologyMedicinePediatrics
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy